© Florida Institue for Clinical Research | Privacy Policy
Website by 
Cardiovascular Health (Lepodisiran)
Lilly J3L-MC-EZEF Lp(a)
The purpose of this study is to investigate the effect of Lepodisiran on the reduction of major adverse cardiovascular events in adults with elevated Lipoprotein(a).
To participate you must:
- Be at least 18 years of age
- Have Lp(a) ≥ 175 nmol/ L at prescreening
- Have documented Cardiovascular disease or be at risk for a first cardiovascular event
- Female ≥ 70 years of age or Male ≥ 65 years with 3 risk factors:
- Current tobacco use
- Diagnosis of hypertension
- Kidney disease
- Diabetes
- Hyperlipidemia